Reconciliation of non-GAAP financial measures related to the DePuy ASC Hip recall program amounted to $412 million in the fourth quarter, up from $280 million in the fourth quarter of 2010. At the 12 months end, the costs amounted to $521 million, up from $280 million in 2010.
The company reported fourth quarter worldwide revenue of $678 million, which is a 5.9 percent increase over the same period in 2010. However, domestic sales dropped 4 percent to $775 million. For the full year, DePuy reported $5.8 billion worldwide, which was a 4 percent increase over last year. Domestic sales for 2011 experienced a 1.7 percent decrease to $3 billion.
Related Articles on Orthopedic Devices:
18 Orthopedic Device Company Partnerships & Acquisitions
Pioneer Surgical Opens Expanded North Carolina Manufacturing Facility
DePuy Pulls Custom Joint Replacements After FDA Warning
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.